Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Akebia Therapeutics Inc
AKBA | US
1.43
USD0
0%
AKBA | US
Loading StockChartView...
About Akebia Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
1.43
Open
1.42
High
1.45
Low
1.41
Akebia Therapeutics Inc. a biopharmaceutical company focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat) an oral hypoxia-inducible factor prolyl hydroxylase which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics Inc. has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge Massachusetts.
View LessAKBA | US
Risk
65.7
Sharpe
-0.54
Luna's Score
40/100
Recommendation
Sell
Luna says (AKBA | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
What's not Working
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
79.7%1 month
65.7%3 months
67.5%6 months
80.0%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.12
Debt to equity
-3.10
Debt to assets
0.48
Ent. to EBITDA
62.58
Ent. to rev.
1.66
PEG
-
Other Fundamentals
EBITDA
4.08M
MarketCap
300.71M
MarketCap(USD)
300.71M
Div. yield
-
Op. margin
-19.99
Erngs. growth
-
Rev. growth
-22.60
Ret. on equity
-553.45
Short ratio
12.81
Short perc.
9.04
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.27
Range1M
0.29
Range3M
0.46
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.04
Price X volume
3.39M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 62.58 | 0.53 | Expensive |
| Ent. to Revenue | 1.66 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.12 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 67.53 | 72.80 | Par |
| Debt to Equity | -3.10 | -1.23 | Cheaper |
| Debt to Assets | 0.48 | 0.25 | Expensive |
| Market Cap | 300.71M | 3.66B | Emerging |
